CClinicalTrials.gg
CompletedNCT02787681Updated Nov 9, 2020Results posted

Multi-center Evaluation of the NEMO Gauge to Aid in Correct Positioning of the Endotracheal Tube

An interventional study of NEMO Gauge in Respiratory Failure, sponsored by Loma Linda University. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-09.

Sponsored by Loma Linda University · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
71
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this study is to verify the safety and accuracy of an FDA-approved device called the NEMO™ Gauge to aide in the proper positioning of the endotracheal tube (ETT), inserted in the lungs of patients admitted to the intensive care unit. The hope is that the NEMO™ Gauge is able to properly determine the correct position of the endotracheal tube without the use of a chest radiograph (chest x-ray). The study investigators anticipate sixty-eight (68) subjects will participate in this study at three (3) study centers in the Inland Empire of Southern California, with subjects being enrolled at Loma Linda University Medical Center, Riverside University Medical Center and Loma Linda Veterans Affairs Hospital.

02

Conditions studied

  • Respiratory Failure
03

In context

Respiratory Insufficiency

1,650 studies on the registry are indexed under Respiratory Insufficiency; 296 are open to participants now.

This study's enrollment of 71 is above the median of 55 across 1,043 interventional studies indexed under Respiratory Insufficiency.

Browse Respiratory Insufficiency studies →

Lead sponsor

Loma Linda University is the lead sponsor of 297 studies on the registry; 48 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 23 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Adult patients ≥ 18 years of age admitted to the intensive care unit (ICU)
  2. Patients who have been intubated or at high risk of being intubated, requiring confirmation of ETT position after intubation as determined by the clinical team
  3. Endotracheal tube size 7.0 mm to 8.5 mm in diameter

Exclusion criteria

Exclusion Criteria:

  1. Patients with active hemoptysis
  2. Patients with known tracheal or bronchial masses prior to endotracheal intubation
  3. Patients with known tracheal or bronchial abnormalities requiring surgical repair
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
71 participants (actual)

Study arms

  • Experimental
    NEMO Gauge

    Measurement and adjustment of endotracheal tube position by stylet.

    Device: NEMO Gauge

Interventions

  • DeviceNEMO Gauge

    Measurement and adjustment of endotracheal tube position by stylet.

06

What researchers measure

Primary outcomes

  1. Number of Correct Endotracheal Tube Position

    The number of patients with correct Endotracheal tube position

    Time frame: Immediate, post-intervention

07

Results

Posted Nov 9, 2020

Participant flow

Participant flow — Overall Study
MilestoneNEMO Gauge
Started71
Completed69
Not completed2

Outcome measures

PrimaryNumber of Correct Endotracheal Tube Position

The number of patients with correct Endotracheal tube position

Time frame:
Immediate, post-intervention
Reported as:
Count of participants · Participants
Number of Correct Endotracheal Tube Position
ParticipantsNEMO Gauge
Number of Correct Endotracheal Tube Position64

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NEMO Gauge0/71 (0%)0/71 (0%)0/71 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)NEMO Gauge
Mean56.2 ± 19.5
Sex: Female, Male
Sex: Female, Male(Participants)NEMO Gauge
Female22
Male47
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)NEMO Gauge
BMI
BMI(kg/m2)NEMO Gauge
Mean31 ± 13.8
Acute Respiratory Failure (Reason for Admission)
Acute Respiratory Failure (Reason for Admission)(Participants)NEMO Gauge
Count of participants52
Sepsis (Reason for Admission)
Sepsis (Reason for Admission)(Participants)NEMO Gauge
Count of participants14
Gastrointestinal (Reason for Admission)
Gastrointestinal (Reason for Admission)(Participants)NEMO Gauge
Count of participants13
Neuromuscular (Reason for Admission)
Neuromuscular (Reason for Admission)(Participants)NEMO Gauge
Count of participants11

7 further baseline measures are reported on the registry.

08

Study locations

3 sites
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • VA Loma Linda Healthcare System
    Loma Linda, California 92357, United States
  • Riverside University Medical Center
    Moreno Valley, California 92555, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 21, 2016

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02787681
Lead sponsor
Loma Linda University
Responsible party
H. Bryant Nguyen (Professor of Medicine, Loma Linda University) — Principal investigator
First posted
Jun 1, 2016
Start date
Aug 15, 2016
Primary completion
Jul 14, 2017
Completion
Jul 14, 2017
Results posted
Nov 9, 2020
Last update
Nov 9, 2020

Study contacts

H. Bryant Nguyen, MD
principal investigator · Loma Linda University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion